A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate The Efficacy And Safety Of Oral PF-04136309 500 Mg BID In Subjects With Chronic HCV Infection And Raised Aminotransferases.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate The Efficacy And Safety Of Oral PF-04136309 500 Mg BID In Subjects With Chronic HCV Infection And Raised Aminotransferases.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs PF 4136309 (Primary)
  • Indications Hepatitis C
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Mar 2012 Actual patient number changed from 21 to 24 as reported by ClinicalTrials.gov.
    • 19 Mar 2012 Actual end date (1 Feb 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top